IV Secukinumab Trials Hit Primary Endpoints in PsA, AxSpA :

Two phase 3 trials of the recently approved IV formulation of secukinumab showed its efficacy vs placebo in treating psoriatic arthritis and axial spondyloarthritis.

Related Keywords

New York , United States , Oregon , Alanj Kivitz , , Assessment Of The Spondyloarthritis International Society , American College Of Rheumatology , Clinical Research , Altoona Center , Oregon Health Science University , Drug Administration , American College , Spondyloarthritis International Society , Atul Deodhar , Oregon Health , Science University , Psoriatic Arthritis , Ankylosing Spondylitis , Arthritis , Oint Inflammation , Biologic Therapy , Hospitals , Interleukins , Intravenous Iv , Intravenous , Tv , Practice Management , Pain Management , Back Pain , Adherence , Dherence To Medication Issues For Patients , Blood , Clinical Trials , Linical Studies , Insurance , Medicare , Monoclonal Antibody , Etuximab , Ituximab , Inew Yo ,